Edward M. Messing - Publications

University of Rochester, Rochester, NY 
Molecular Biology, Oncology, Cell Biology

147 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, et al. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urologic Oncology. PMID 32430255 DOI: 10.1016/j.urolonc.2020.04.026  0.48
2020 Gurung PMS, Messing EM, Joseph JV, Wu G. EDITORIAL COMMENT. Urology. 136: 110-111. PMID 32033663 DOI: 10.1016/j.urology.2019.09.048  0.88
2019 Chen J, Chou F, Yeh S, Ou Z, Shyr C, Huang C, Xiang Z, Sun Y, Messing E, Zu X, Chang C. Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling. Oncogene. PMID 31506605 DOI: 10.1038/s41388-019-0964-6  0.56
2019 Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, ... ... Messing EM, et al. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. European Urology Oncology. 2: 257-264. PMID 31200839 DOI: 10.1016/j.euo.2018.08.008  0.32
2018 Wu CH, Silvers CR, Messing EM, Lee YF. Bladder cancer extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of non-malignant cells. The Journal of Biological Chemistry. PMID 30593508 DOI: 10.1074/jbc.RA118.006682  0.32
2018 Berrondo C, Feng C, Kukreja JB, Messing EM, Joseph JV. Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy: A prospective randomized clinical trial. Urologic Oncology. PMID 30558984 DOI: 10.1016/j.urolonc.2018.10.029  0.32
2018 Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. Jama. 319: 1880-1888. PMID 29801011 DOI: 10.1001/jama.2018.4657  0.88
2018 Truong M, Frye T, Messing E, Miyamoto H. Historical and contemporary perspectives on cribriform morphology in prostate cancer. Nature Reviews. Urology. PMID 29713007 DOI: 10.1038/s41585-018-0013-1  0.48
2018 Tao L, Qiu J, Slavin S, Ou Z, Liu Z, Ge J, Guancial EA, Messing EM, Chang C, Yeh S. Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals. Cancer Letters. PMID 29684419 DOI: 10.1016/j.canlet.2018.03.045  0.56
2018 Han Z, Zhang Y, Sun Y, Chen J, Chang C, Wang X, Yeh S. ERβ-mediated alteration of circATP2B1 and miR-204-3p signaling promotes invasion of clear cell renal cell carcinoma. Cancer Research. PMID 29490945 DOI: 10.1097/01.JU.0000555350.06182.00  0.76
2017 Silvers CR, Miyamoto H, Messing EM, Netto GJ, Lee YF. Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. Oncotarget. 8: 91199-91208. PMID 29207636 DOI: 10.18632/oncotarget.20043  0.48
2017 Truong M, Wang B, Gordetsky JB, Nix JW, Frye TP, Messing EM, Thomas JV, Feng C, Rais-Bahrami S. Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy. Cancer. PMID 28976544 DOI: 10.1002/cncr.31051  0.32
2017 Horovitz D, Meng Y, Joseph JV, Feng C, Wu G, Rashid H, Messing EM. The role of urinary cytology when diagnostic workup is suspicious for upper tract urothelial carcinoma but tumour biopsy is nonconfirmatory. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 11: E285-E290. PMID 28761589 DOI: 10.5489/cuaj.4150  0.88
2017 Horovitz D, Lu X, Feng C, Messing EM, Joseph JV. Rate of Symptomatic Lymphocele Formation after Extraperitoneal vs. Transperitoneal Robot Assisted Radical Prostatectomy and Bilateral Pelvic Lymphadenectomy. Journal of Endourology. PMID 28741376 DOI: 10.1089/end.2017.0153  0.32
2017 Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. A Comprehensive Analysis of Cribriform Morphology on MR/US Fusion Biopsy Correlated with Radical Prostatectomy Specimens. The Journal of Urology. PMID 28728994 DOI: 10.1016/j.juro.2017.07.037  0.48
2017 Truong M, Rais-Bahrami S, Nix JW, Messing EM, Miyamoto H, Gordetsky JB. Perineural Invasion by Prostate Cancer on MR/US Fusion Targeted Biopsy is Associated with Extraprostatic Extension and Early Biochemical Recurrence after Radical Prostatectomy. Human Pathology. PMID 28705708 DOI: 10.1016/j.humpath.2017.06.017  0.48
2017 Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric MRI: Correlation with Final Histopathology. The Journal of Urology. PMID 28163032 DOI: 10.1016/j.juro.2017.01.077  0.48
2017 Horovitz D, Feng C, Messing EM, Joseph JV. Extraperitoneal vs. transperitoneal robot-assisted radical prostatectomy in patients with a history of prior inguinal hernia repair with mesh. Journal of Robotic Surgery. PMID 28120135 DOI: 10.1007/s11701-017-0678-0  0.32
2017 Horovitz D, Feng C, Messing EM, Joseph JV. Extraperitoneal vs. Transperitoneal Robot-Assisted Radical Prostatectomy in the Setting of Prior Abdominal or Pelvic Surgery. Journal of Endourology. PMID 28073298 DOI: 10.1089/end.2016.0706  0.32
2016 Meng Y, Bernie HL, Weng TH, Ling DA, Messing EM, Guancial E. Complete Remission of Locally Advanced Penile Squamous Cell Carcinoma after Multimodality Treatment. Rare Tumors. 8: 6651. PMID 28191294 DOI: 10.4081/rt.2016.6651  0.32
2016 Doucette C, Grossman CE, Messing E, Joseph J, Zhang H. High Incidence of Pathologic Upgrading and Upstaging in Clinically Unfavorable Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: E244. PMID 27674162 DOI: 10.1016/j.ijrobp.2016.06.1237  0.44
2016 Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. Plos One. 11: e0155503. PMID 27187160 DOI: 10.1371/journal.pone.0155503  0.84
2016 Baack Kukreja JE, Kiernan M, Schempp B, Siebert A, Hontar A, Dolan J, Noyes K, Dozier A, Ghazi A, Rashid HH, Wu G, Messing EM. Quality Improvement in Cystectomy Care with Enhanced Recovery (QUICCER Study). Bju International. PMID 27128851 DOI: 10.1111/bju.13521  0.84
2016 Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S. Targeting estrogen/estrogen receptor alpha will enhance Bacillus Calmette-Guerin efficacy in bladder cancer. Oncotarget. PMID 27092883 DOI: 10.18632/oncotarget.8756  0.84
2016 Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF. Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer. Oncotarget. PMID 26981774 DOI: 10.18632/oncotarget.8024  0.48
2016 Baack Kukreja JE, Levey HR, Ghazi A, Rashid H, Wu G, Messing EM, Dolan JG. Cost-Effectiveness of Extended Duration Venous Thromboembolism Prophylaxis in High Risk Urological Oncology Surgical Patients Urology Practice. 3: 262-269. DOI: 10.1016/j.urpr.2015.08.004  0.84
2016 Ahmadi H, Jewett MAS, Shore ND, Alkazaz N, Almatar A, Latini DM, Legere L, Messing E, Thrasher JB, Lee CT. The Need for Survivorship Care in Genitourinary Cancers: Considerations from SUO and LUGPA Urology Practice. 3: 62-69. DOI: 10.1016/j.urpr.2015.01.003  0.84
2015 Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, Mueller E, Streeper N, Uhlman MA, Svatek RS, Messing EM, Lotan Y. Microscopic hematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. Bju International. PMID 26435378 DOI: 10.1111/bju.13345  0.84
2015 Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K. Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. 6: 357-75. PMID 26323372 DOI: 10.1007/s13300-015-0128-9  0.84
2015 Shang Z, Li Y, Zhang M, Tian J, Han R, Shyr CR, Messing E, Yeh S, Niu Y, Chang C. Anti-androgen therapy with Hydroxyflutamide or androgen receptor degradation enhancer ASC-J9® enhances BCG efficacy to better suppress bladder cancer progression. Molecular Cancer Therapeutics. PMID 26264279 DOI: 10.1158/1535-7163.MCT-14-1055-T  0.84
2015 Rojas KD, Montero ML, Yao J, Messing E, Fazili A, Joseph J, Ou Y, Rubens DJ, Parker KJ, Davatzikos C, Castaneda B. Methodology to study the three-dimensional spatial distribution of prostate cancer and their dependence on clinical parameters. Journal of Medical Imaging (Bellingham, Wash.). 2: 037502. PMID 26236756 DOI: 10.1117/1.JMI.2.3.037502  0.4
2015 Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, Mohile SG, Fung C. Bladder cancer in the elderly patient: challenges and solutions. Clinical Interventions in Aging. 10: 939-49. PMID 26089655 DOI: 10.2147/CIA.S74322  0.84
2015 Kukreja JE, Levey HR, Scosyrev E, Kiernan M, Berrondo C, McNamee C, Wu G, Joseph JV, Ghazi A, Rashid H, Dozier A, Messing EM. Effectiveness and safety of extended-duration prophylaxis for venous thromboembolism in major urologic oncology surgery. Urologic Oncology. PMID 25637953 DOI: 10.1016/j.urolonc.2014.12.010  0.84
2015 Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, ... ... Messing E, et al. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urologic Oncology. 33: 53-64. PMID 25065704 DOI: 10.1016/j.urolonc.2014.06.013  0.84
2015 Kolesar JM, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Kim K, Tangrea JA, Parnes HL, House MG, Gee J, Messing E, Bailey HH. Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 21: 128-31. PMID 24642450 DOI: 10.1177/1078155214528552  0.84
2014 Baack Kukreja JE, Scosyrev E, Brasacchio RA, Toy EP, Messing EM, Wu G. Bladder cancer incidence and mortality in patients treated with radiation for uterine cancer. Bju International. 114: 844-51. PMID 26010047 DOI: 10.1111/bju.12543  0.88
2014 Yasmin-Karim S, King MR, Messing EM, Lee YF. E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis. Oncotarget. 5: 12097-110. PMID 25301730 DOI: 10.18632/oncotarget.2503  0.32
2014 Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. Oncotarget. 5: 7917-35. PMID 25277204  0.52
2014 Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urologic Oncology. 32: 826-32. PMID 24931270 DOI: 10.1016/j.urolonc.2014.01.020  0.84
2014 Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era Anticancer Research. 34: 2405-2412. PMID 24778051  0.84
2014 Dunne RF, Sahasrabudhe DM, Messing EM, Jean-Gilles J, Fung C. A case series of transformation of teratoma to primitive neuroectodermal tumor: evolving management of a rare malignancy. Rare Tumors. 6: 5268. PMID 24711909 DOI: 10.4081/rt.2014.5268  0.84
2014 Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK, Scosyrev E, Messing EM, Lee YF. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. The Journal of Urology. 192: 583-92. PMID 24530986 DOI: 10.1016/j.juro.2014.02.035  0.32
2014 Slavin S, Yeh CR, Da J, Yu S, Miyamoto H, Messing EM, Guancial E, Yeh S. Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. Carcinogenesis. 35: 1301-9. PMID 24374826 DOI: 10.1093/carcin/bgt488  0.52
2013 Travis LB, Messing EM, Hyrien O, Chen R, Milano MT, Brasacchio RA, Chen Y. PSA-detected prostate cancer in the United States: A population-based study of 70,345 men with AJCC stage T1cN0M0 disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 50. PMID 28137053 DOI: 10.1200/jco.2013.31.6_suppl.50  0.52
2013 Pandya C, Fung C, Sahasrabudhe DM, Brasacchio RA, Messing EM, Sievert L, Mohile SG. Characteristics and outcomes of elderly patients with systemic prostate cancer (PCa) treated with peripheral androgen blockade (PAB). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 226. PMID 28136994 DOI: 10.1200/jco.2013.31.6_suppl.226  0.52
2013 Zhang H, Messing EM, Travis LB, Hyrien O, Chen R, Milano MT, Chen Y. Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men. Frontiers in Oncology. 3: 312. PMID 24392353 DOI: 10.3389/fonc.2013.00312  0.84
2013 Hsu JW, Yin PN, Wood R, Messing J, Messing E, Lee YF. 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer. Oncotarget. 4: 2397-406. PMID 24353168  0.84
2013 Dogra VS, Chinni BK, Valluru KS, Joseph JV, Ghazi A, Yao JL, Evans K, Messing EM, Rao NA. Multispectral Photoacoustic Imaging of Prostate Cancer: Preliminary Ex-vivo Results. Journal of Clinical Imaging Science. 3: 41. PMID 24228210 DOI: 10.4103/2156-7514.119139  0.36
2013 Yang DR, Lin SJ, Ding XF, Miyamoto H, Messing E, Li LQ, Wang N, Chang C. Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion. Urology. 81: 1109.e1-6. PMID 23522297 DOI: 10.1016/j.urology.2012.12.027  0.48
2013 Ghazi A, Scosyrev E, Patel H, Messing EM, Joseph JV. Complications associated with extraperitoneal robot-assisted radical prostatectomy using the standardized Martin classification. Urology. 81: 324-31. PMID 23374793 DOI: 10.1016/j.urology.2012.07.106  0.32
2013 Weight CJ, Miller DC, Campbell SC, Derweesh IH, Lane BR, Messing EM. The management of a clinical t1b renal tumor in the presence of a normal contralateral kidney. The Journal of Urology. 189: 1198-202. PMID 23337186 DOI: 10.1016/j.juro.2013.01.030  0.84
2013 Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. European Urology. 63: 1049-58. PMID 23313034 DOI: 10.1016/j.eururo.2012.12.062  0.84
2012 Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, Messing EM, Miller SD, Peterson AC, Turk TM, Weitzel W. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. The Journal of Urology. 188: 2473-81. PMID 23098784 DOI: 10.1016/j.juro.2012.09.078  0.84
2012 Baran TM, Wilson JD, Mitra S, Yao JL, Messing EM, Waldman DL, Foster TH. Optical property measurements establish the feasibility of photodynamic therapy as a minimally invasive intervention for tumors of the kidney. Journal of Biomedical Optics. 17: 98002-1. PMID 23085928 DOI: 10.1117/1.JBO.17.9.098002  0.84
2012 Byler TK, Leocadio D, Shapiro O, Bratslavsky G, Stodgell CJ, Wood RW, Messing EM, Reeder JE. Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. Bmc Urology. 12: 21. PMID 22898175 DOI: 10.1186/1471-2490-12-21  0.84
2012 Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer. 118: 5768-76. PMID 22847578 DOI: 10.1002/cncr.27503  0.88
2012 Tobis S, Knopf JK, Silvers CR, Marshall J, Cardin A, Wood RW, Reeder JE, Erturk E, Madeb R, Yao J, Singer EA, Rashid H, Wu G, Messing E, Golijanin D. Near infrared fluorescence imaging after intravenous indocyanine green: initial clinical experience with open partial nephrectomy for renal cortical tumors. Urology. 79: 958-64. PMID 22336035 DOI: 10.1016/j.urology.2011.10.016  0.84
2012 Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, et al. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prevention Research (Philadelphia, Pa.). 5: 621-30. PMID 22293631 DOI: 10.1158/1940-6207.CAPR-11-0455  0.84
2012 Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. Bju International. 109: 1716-26. PMID 22221549 DOI: 10.1016/j.juro.2012.02.453  0.56
2012 Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 118: 3062-70. PMID 22006014 DOI: 10.1002/cncr.26392  0.88
2012 Lloyd GL, Singh MJ, Messing EM. An unusual cause of an enhancing retroperitoneal mass. Urology. 79: e61-2. PMID 21945280 DOI: 10.1016/j.urology.2011.06.042  0.84
2012 Gordetsky J, Scosyrev E, Rashid H, Wu G, Silvers C, Golijanin D, Messing EM, Yao JL. Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 140-4. PMID 21909079 DOI: 10.1038/modpathol.2011.137  0.88
2012 Scosyrev E, Messing EM, van Wijngaarden E, Peterson DR, Sahasrabudhe D, Golijanin D, Fisher SG. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer. 118: 72-81. PMID 21720989 DOI: 10.1002/cncr.26238  0.84
2011 Gordetsky J, Findeis-Hosey J, Erturk E, Messing EM, Yao JL, Miyamoto H. Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 5: E47-51. PMID 21806893 DOI: 10.5489/cuaj.10144  0.48
2011 Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). Bju International. 108: 693-9. PMID 21105991 DOI: 10.1111/j.1464-410X.2010.09900.x  0.84
2011 Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, van Rhijn BW, Bostrom P, Yao J, ... ... Messing E, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. Bju International. 108: 24-30. PMID 21070579 DOI: 10.1111/j.1464-410X.2010.09834.x  0.84
2011 He X, Wang J, Messing EM, Wu G. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness. Oncogene. 30: 535-47. PMID 20871634 DOI: 10.1038/onc.2010.427  0.88
2010 Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank session 3: Prevention of bladder cancer. Urologic Oncology. 28: 338-42. PMID 20439034 DOI: 10.1016/j.urolonc.2009.06.018  0.84
2010 Madeb R, Golijanin D, Knopf J, Davis M, Feng C, Fender A, Stephenson L, Messing EM. Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology. 75: 20-5. PMID 19913883 DOI: 10.1016/j.urology.2009.06.107  0.32
2009 Yan K, Li L, Joseph J, Rubens DR, Messing EM, Liao L, Yu Y. A real-time prostate cancer detection technique using needle insertion force and patient-specific criteria during percutaneous intervention. Medical Physics. 36: 3356-62. PMID 19673230 DOI: 10.1118/1.3148834  0.4
2009 Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, Knopf J, Lyman GH, Messing EM. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 115: 2660-70. PMID 19455607 DOI: 10.1002/cncr.24311  0.84
2009 Messing EM, Madeb R, Feng C, Stephenson L, Gilchrist KW, Young T, Gee J. Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2443-9. PMID 19332735 DOI: 10.1200/JCO.2008.16.5951  0.32
2009 Scosyrev E, Yao J, Messing E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology. 73: 822-7. PMID 19193403 DOI: 10.1016/j.urology.2008.11.042  0.36
2009 Chen M, Hsu I, Wolfe A, Radovick S, Huang K, Yu S, Chang C, Messing EM, Yeh S. Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice. Endocrinology. 150: 251-9. PMID 18755802 DOI: 10.1210/en.2008-0044  0.56
2009 Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urologic Oncology. 27: 496-501. PMID 18639470 DOI: 10.1016/j.urolonc.2008.05.004  0.32
2008 Sahasrabudhe DM, Messing E, Schoen SR, Feng C, Joseph J, Constantino A, VidyaRao S, Kohli M. A cross-sectional study of angiopoietin-1 (Ang-1) in early and advanced prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5137. PMID 27948214 DOI: 10.1200/jco.2008.26.15_suppl.5137  0.84
2008 Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 105: 12182-7. PMID 18723679 DOI: 10.1073/pnas.0804700105  0.84
2008 Johnson AM, O'Connell MJ, Messing EM, Reeder JE. Decreased bladder cancer growth in parous mice. Urology. 72: 470-3. PMID 18533230 DOI: 10.1016/j.urology.2008.04.028  0.84
2008 Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder JE. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. Bmc Urology. 8: 7. PMID 18433501 DOI: 10.1186/1471-2490-8-7  0.84
2008 Zhang M, Nigwekar P, Castaneda B, Hoyt K, Joseph JV, di Sant'Agnese A, Messing EM, Strang JG, Rubens DJ, Parker KJ. Quantitative characterization of viscoelastic properties of human prostate correlated with histology. Ultrasound in Medicine & Biology. 34: 1033-42. PMID 18258350 DOI: 10.1016/j.ultrasmedbio.2007.11.024  0.84
2008 Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer. Expert Opinion On Pharmacotherapy. 9: 211-28. PMID 18201145 DOI: 10.1517/14656566.9.2.211  0.48
2008 Hutson PR, Oettel K, Douglas J, Ritter M, Messing E, Staab MJ, Alberti D, Horvath D, Wilding G. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemotherapy and Pharmacology. 62: 373-7. PMID 17922273 DOI: 10.1007/s00280-007-0613-6  0.32
2007 Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Molecular Cancer Research : McR. 5: 967-80. PMID 17855664 DOI: 10.1158/1541-7786.MCR-06-0318  0.36
2007 Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, ... ... Messing EM, et al. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomarkers : Section a of Disease Markers. 3: 1-33. PMID 17655039  0.84
2007 Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. Journal of the National Cancer Institute. 99: 558-68. PMID 17406000 DOI: 10.1093/jnci/djk113  0.56
2006 Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. Jama. 296: 2329-35. PMID 17105795 DOI: 10.1001/jama.296.19.2329  0.84
2006 Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, Wegenke JD, Stephenson L, Gee J, Feng C. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 107: 2173-9. PMID 17029275 DOI: 10.1002/cncr.22224  0.32
2006 Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. The Journal of Urology. 176: 500-4. PMID 16813878 DOI: 10.1016/j.juro.2006.03.061  0.32
2006 Wood RW, Baggs RB, Schwarz EM, Messing EM. Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate. Urology. 67: 1324-8. PMID 16765198 DOI: 10.1016/j.urology.2005.12.019  0.84
2006 Johnson AM, Conover DL, Huang J, Messing EM, Ning R, O'Connell MJ, Rossi MA, Sun TT, Wood RW, Wu XR, Reeder JE. Early detection and measurement of urothelial tumors in mice. Urology. 67: 1309-14. PMID 16765196 DOI: 10.1016/j.urology.2005.12.011  0.84
2006 Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. The Lancet. Oncology. 7: 472-9. PMID 16750497 DOI: 10.1016/S1470-2045(06)70700-8  0.4
2005 Ni J, Wen X, Yao J, Chang HC, Yin Y, Zhang M, Xie S, Chen M, Simons B, Chang P, di Sant'Agnese A, Messing EM, Yeh S. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Research. 65: 9807-16. PMID 16267002 DOI: 10.1158/0008-5472.CAN-05-1334  0.52
2005 Miyamoto H, Messing EM, Chang C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nature Clinical Practice. Oncology. 2: 236-7. PMID 16264955 DOI: 10.1038/ncponc0168  0.48
2005 Taylor LS, Rubens DJ, Porter BC, Wu Z, Baggs RB, di Sant'Agnese PA, Nadasdy G, Pasternack D, Messing EM, Nigwekar P, Parker KJ. Prostate cancer: three-dimensional sonoelastography for in vitro detection. Radiology. 237: 981-5. PMID 16251396 DOI: 10.1148/radiol.2373041573  0.84
2005 Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B, Qian J, Bostwick DG. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. The Journal of Urology. 174: 1238-41. PMID 16145377 DOI: 10.1097/01.ju.0000173918.84006.4d  0.84
2005 Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Molecular Carcinogenesis. 44: 1-10. PMID 16044418 DOI: 10.1002/mc.20121  0.48
2005 Li Z, Wang D, Messing EM, Wu G. VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. Embo Reports. 6: 373-8. PMID 15776016 DOI: 10.1038/sj.embor.7400377  0.88
2005 Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, Culkin DJ, Diokno A, Hanno P, Landis JR, Madigan R, Messing EM, Nickel JC, Sant GR, Warren J, et al. A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. The Journal of Urology. 173: 1186-91. PMID 15758738 DOI: 10.1097/01.ju.0000152337.82806.e8  0.84
2005 Wang D, Li Z, Messing EM, Wu G. The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway. The Journal of Biological Chemistry. 280: 16393-401. PMID 15713673 DOI: 10.1074/jbc.M413897200  0.88
2005 Madeb R, Nicholson C, Borhan A, Erturk E, Messing EM. Urologic Concerns in Critical Care Critical Care. 317-334. DOI: 10.1016/B978-0-323-02262-0.50034-8  0.84
2004 Messing EM, Manola J, Sarosdy M, Wilding G, Crawford D, Kiernan M, Trump D. Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4570. PMID 28015974 DOI: 10.1200/jco.2004.22.14_suppl.4570  0.32
2004 Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. The Prostate. 61: 332-53. PMID 15389811 DOI: 10.1002/pros.20115  0.48
2004 Leung YY, Schwarz EM, Silvers CR, Messing EM, Wood RW. Uroflow in murine urethritis. Urology. 64: 378-82. PMID 15302511 DOI: 10.1016/j.urology.2004.04.036  0.84
2004 Miyamoto H, Messing EM. Early versus late hormonal therapy for prostate cancer. Current Urology Reports. 5: 188-96. PMID 15161567  0.48
2004 Rashid HH, Reeder JE, O'Connell MJ, Zhang CO, Messing EM, Keay SK. Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator. Bmc Urology. 4: 3. PMID 15068487 DOI: 10.1186/1471-2490-4-3  0.36
2004 Wright KO, Messing EM, Reeder JE. DBCCR1 mediates death in cultured bladder tumor cells. Oncogene. 23: 82-90. PMID 14712213 DOI: 10.1038/sj.onc.1206642  0.36
2004 Wang D, Li Z, Schoen SR, Messing EM, Wu G. A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling. Biochemical and Biophysical Research Communications. 313: 320-6. PMID 14684163 DOI: 10.1016/j.bbrc.2003.11.124  0.84
2003 Reeder JE, Sowden MP, Messing EM, Klover P, Villa-Moruzzi E, Ludlow JW. Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line. Cancer Cell International. 3: 12. PMID 12914669 DOI: 10.1186/1475-2867-3-12  0.84
2003 Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. The Journal of Urology. 170: 810-5. PMID 12913705 DOI: 10.1097/01.ju.0000083020.06212.3d  0.84
2003 Na X, Duan HO, Messing EM, Schoen SR, Ryan CK, di Sant'Agnese PA, Golemis EA, Wu G. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. The Embo Journal. 22: 4249-59. PMID 12912922 DOI: 10.1093/emboj/cdg410  0.84
2003 Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. The Journal of Urology. 170: 588-92. PMID 12853836 DOI: 10.1097/01.ju.0000074870.54671.98  0.84
2003 Borhan A, Reeder JE, O'Connell MJ, Wright KO, Wheeless LL, di Sant'Agnese PA, McNally ML, Messing EM. Grade progression and regression in recurrent urothelial cancer. The Journal of Urology. 169: 2106-9. PMID 12771728 DOI: 10.1097/01.ju.0000067160.09881.45  0.36
2003 Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. The Embo Journal. 22: 1857-67. PMID 12682018 DOI: 10.1093/emboj/cdg173  0.84
2003 Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1214-22. PMID 12663707 DOI: 10.1200/JCO.2003.02.005  0.32
2002 Wright KO, Messing EM, Reeder JE. Increased expression of the acid sphingomyelinase-like protein ASML3a in bladder tumors. The Journal of Urology. 168: 2645-9. PMID 12442002 DOI: 10.1097/01.ju.0000037848.19383.88  0.36
2002 Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Research. 62: 6039-44. PMID 12414626  0.48
2002 Gottlieb RH, La TC, Erturk EN, Sotack JL, Voci SL, Holloway RG, Syed L, Mikityansky I, Tirkes AT, Elmarzouky R, Zwemer FL, Joseph JV, Davis D, DiGrazio WJ, Messing EM. CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomes. Radiology. 225: 441-9. PMID 12409578 DOI: 10.1148/radiol.2252020101  0.32
2002 Sessions A, Eichel L, Kassahun M, Messing EM, Schwarz E, Wood RW. Continuous bladder infusion methods for studying voiding function in the ambulatory mouse. Urology. 60: 707-13. PMID 12385948 DOI: 10.1016/S0090-4295(02)01810-1  0.84
2002 Wang D, Li Z, Messing EM, Wu G. Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. The Journal of Biological Chemistry. 277: 36216-22. PMID 12147692 DOI: 10.1074/jbc.M205111200  0.88
2002 Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochemical and Biophysical Research Communications. 294: 700-9. PMID 12056827 DOI: 10.1016/S0006-291X(02)00534-X  0.84
2002 Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 99: 7408-13. PMID 12032296 DOI: 10.1073/pnas.102014399  0.52
2002 Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. The Journal of Biological Chemistry. 277: 4656-62. PMID 11739384 DOI: 10.1074/jbc.M108269200  0.84
2001 Eichel L, Scheidweiler K, Kost J, Shojaie J, Schwarz E, Messing E, Wood R. Assessment of murine bladder permeability with fluorescein: Validation with cyclophosphamide and protamine Urology. 58: 113-118. PMID 11445501 DOI: 10.1016/S0090-4295(01)01007-X  0.84
2001 Wood R, Pittelli R, Foster D, Mayer R, Messing EM. Human bladder permeability assessment using intravesical fluorescein clearance rate Urology. 57: 131-132. PMID 11378133  0.84
2001 Wood R, Eichel L, Messing EM, Schwarz E. Automated noninvasive measurement of cyclophosphamide-induced changes in murine micturition frequency and volume and demonstration of pharmacologic sensitivity Urology. 57: 115-116. PMID 11378091  0.84
2001 Eichel LS, Sessions AE, Messing EM, Schwarz E, Wood RW. Continuous bladder infusion methods for studying voiding function in ambulatory mice. Urology. 57: 115. PMID 11378089  0.84
2001 Wood R, Eichel L, Messing EM, Schwarz E. Automated noninvasive measurement of cyclophosphamide-induced changes in murine voiding frequency and volume Journal of Urology. 165: 653-659. PMID 11176453 DOI: 10.1097/00005392-200102000-00089  0.84
1999 Jung I, Reeder JE, Cox C, Siddiqui JF, O'Connell MJ, Collins L, Yang Z, Messing EM, Wheeless LL. Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. The Journal of Urology. 162: 1900-3. PMID 10569533 DOI: 10.1016/S0022-5347(05)68064-0  0.36
1999 Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplun M, Simsiman R, Wilding G. Low-dose difluoromethylornithine and polyamine levels in human prostate tissue Journal of the National Cancer Institute. 91: 1416-1417. PMID 10451448 DOI: 10.1093/jnci/91.16.1416  0.84
1998 Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells Proceedings of the National Academy of Sciences of the United States of America. 95: 11083-11088. PMID 9736693 DOI: 10.1073/pnas.95.19.11083  0.84
1998 Reeder JE, O'Connell MJ, Yang Z, Morreale JF, Collins L, Frank IN, Messing EM, Cockett AT, Cox C, Robinson RD, Wheeless LL. DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients. Urology. 51: 58-61. PMID 9610559 DOI: 10.1016/S0090-4295(98)00067-3  0.36
1997 Reeder JE, Morreale JF, O'Connell MJ, Stadler WM, Olopade OF, Messing EM, Wheeless LL. Loss of the CDKN2A/p16 locus detected in bladder irrigation specimens by fluorescence in situ hybridization. The Journal of Urology. 158: 1717-21. PMID 9334586 DOI: 10.1016/S0022-5347(01)64107-7  0.36
1997 Messing E, Pauk D, Schaeffer A, Nieweglowski M, Nyberg LM, Landis JR, Cook YL, Simon LJ. Associations among cystoscopic findings and symptoms and physical examination findings in women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. Urology. 49: 81-5. PMID 9146006 DOI: 10.1016/S0090-4295(99)80336-7  0.84
1995 Messing EM, Young TB, Hunt VB, Newton MA, Bram LL, Vaillancourt A, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD. Hematuria Home Screening: Repeat Testing Results The Journal of Urology. 154: 57-61. PMID 7776456 DOI: 10.1016/S0022-5347(01)67224-0  0.84
1995 D'Alessandro AM, Sollinger HW, Knechtle SJ, Kalayoglu M, Kisken WA, Uehling DT, Moon TD, Messing EM, Bruskewitz RC, Pirsch JD. Living related and unrelated donors for kidney transplantation. A 28-year experience. Annals of Surgery. 222: 353-62; discussion 3. PMID 7677464  0.84
1995 Howard SP, Groch KM, Lindstrom MJ, Messing EM, Gould MN. Proliferation-independent growth factor modulation of the radiation sensitivity of human prostate cells Radiation Research. 143: 229-233. PMID 7631017 DOI: 10.2307/3579162  0.84
1994 Kloth MT, Gee RL, Messing EM, Swaminathan S. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis. 15: 2781-7. PMID 8001235 DOI: 10.1093/carcin/15.12.2781  0.84
1993 Sollinger HW, Messing EM, Eckhoff DE, Pirsch JD, D'Alessandro AM, Kalayoglu M, Knechtle SJ, Hickey D, Belzer FO. Urological complications in 210 consecutive simultaneous pancreas-kidney transplants with bladder drainage. Annals of Surgery. 218: 561-8; discussion 56. PMID 8215647  0.84
1992 Ritter MA, Messing EM, Shanahan TG, Potts S, Choppell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer Journal of Clinical Oncology. 10: 1208-1217. PMID 1378886 DOI: 10.1200/JCO.1992.10.8.1208  0.84
1991 Edelman GC, Sweet ME, Messing EM, Helgerson RB. Treatment of severe electrical burns of the genitalia and perineum by early excision and grafting. Burns : Journal of the International Society For Burn Injuries. 17: 506-9. PMID 1793504 DOI: 10.1016/0305-4179(91)90082-R  0.84
1991 Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ. Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder Journal of Urology. 146: 1631-1636. PMID 1719252 DOI: 10.1016/S0022-5347(17)38202-2  0.84
1991 Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ. The significance of immune cytological diagnostics for bladder carcinoma Oncology Research and Treatment. 14: 385-390. DOI: 10.1159/000217013  0.84
1990 Messing EM, Vaillancourt A. Hematuria screening for bladder cancer Journal of Occupational Medicine. 32: 838-845. PMID 2074507 DOI: 10.1097/00043764-199009000-00016  0.84
1988 Busch DB, Bryan GT, Easterling D, Leventhal H, Messing EM, Cummings KB. Follow-up: recontacting subjects in mutagen exposure monitoring studies. Irb. 10: 9-11. PMID 11650076  0.84
1987 Messing EM, Hanson P, Ulrich P, Erturk E. Epidermal growth factor - Interactions with normal and malignant urothelium: In vivo and in situ studies Journal of Urology. 138: 1329-1335. PMID 3499520 DOI: 10.1016/S0022-5347(17)43593-2  0.84
1984 Messing EM, Bubbers JE, Whitmore KE, deKernion JB, Nestor MS, Fahey JL. Murine hybridoma antibodies against human transitional carcinoma-associated antigens Journal of Urology. 132: 167-172. PMID 6202893 DOI: 10.1016/S0022-5347(17)49512-7  0.84
Show low-probability matches.